This study aimed to evaluate the effectiveness and safety of adding bevacizumab to first-line chemotherapy for patients with metastatic colorectal cancer. The study involved randomly assigning patients to receive either XELOX or FOLFOX-4 and then bevacizumab or a placebo. The primary endpoint was progression-free survival. Results showed that adding bevacizumab resulted in a longer median progression-free survival (9.4 months) compared to the placebo group (8.0 months). However, the median overall survival was similar between the two groups. Response rates were also similar, but the treatment withdrawal rate was higher in the placebo group. The toxicity profile of bevacizumab was consistent with previous trials.

To know more: About the original article click here.